

*This manuscript has been accepted for publication in Otolaryngology-Head and Neck Surgery.*

1 High-efficiency particulate air (HEPA) filters in the era of COVID-19: function  
2 and efficacy  
3  
4

5 David Christopherson<sup>1</sup>, William C. Yao, MD<sup>2</sup>, Mingming Lu, PhD<sup>3</sup>, R. Vijayakumar, PhD<sup>4</sup>, and Ahmad  
6 R. Sedaghat, MD, PhD<sup>1</sup>,

7 <sup>1</sup>Department of Otolaryngology – Head and Neck Surgery, University of Cincinnati College of Medicine,  
8 Cincinnati, OH, USA, <sup>2</sup>Department of Otorhinolaryngology–Head and Neck Surgery, McGovern Medical  
9 School, The University of Texas Health Science Center at Houston, Houston, TX, <sup>3</sup>Department of  
10 Chemical and Environmental Engineering, College of Engineering and Applied Sciences, University of  
11 Cincinnati and <sup>4</sup>Aerfil LLC, Liverpool, New York  
12  
13  
14  
15

16 Funding: None  
17

18 Conflicts of Interest: R. Vijayakumar is consultant in chief at the consulting firm Aerfil, LLC, and he has  
19 also served on and chaired committees on HEPA standards at the U.S. Institute of Environmental  
20 Sciences and Technology as well as the International Organization for Standardization. William C. Yao  
21 serves as a consultant for Stryker (Kalamazoo, MI) and is part of the speakers' bureau for OptiNose US,  
22 Inc. (Yardley, PA).  
23  
24

25 Author contributions:

26 Christopherson: Manuscript design/organization, drafting and revisions, final approval

27 Yao: Manuscript drafting/revisions, final approval

28 Lu: Manuscript drafting/revisions, final approval

29 Vijayakumar: Manuscript drafting/revisions, final approval

30 Sedaghat: Manuscript conception/design/organization, drafting and revisions, final approval  
31  
32  
33

34 Corresponding Author:

35 Ahmad R. Sedaghat, MD, PhD

36 Department of Otolaryngology—Head and Neck Surgery

37 University of Cincinnati College of Medicine

38 Medical Sciences Building Room 6410

39 231 Albert Sabin Way

40 Cincinnati, OH 45267-0528

41 Phone: 513-558-4152

42 Fax: 513-558-3231

43 Email: ahmad.sedaghat@uc.edu  
44

45 Keywords: High efficiency particulate air filter; HEPA; air purifier; Coronavirus; COVID-19; SARS-  
46 CoV-2  
47  
48

*This manuscript has been accepted for publication in Otolaryngology-Head and Neck Surgery.*

49 **Abstract**

50           Aerosol generating procedures (AGPs) in the office represent a major concern for healthcare-  
51 associated infection (HAI) of patients and healthcare providers by SARS-CoV-2, the causative agent for  
52 Coronavirus disease 2019 (COVID-19). Although the Centers for Disease Control and Prevention has not  
53 provided any recommendations for the use of portable air purifiers, air purifiers with high-efficiency  
54 particulate air (HEPA) filters have been discussed as an adjunctive means for decontamination of SARS-  
55 CoV-2 aerosols in healthcare settings. This commentary discusses HEPA filter mechanisms of action,  
56 decontamination time based on efficiency and flow rate, theoretical application to SARS-CoV-2, and  
57 limitations. HEPA filter functionality and prior CDC guidance for SARS-CoV-1 suggest theoretical  
58 efficacy for HEPA filters to decontaminate airborne SARS-CoV-2, although direct studies for SARS-  
59 CoV-2 have not been performed. Any portable HEPA purifier utilization for SARS-CoV-2 should be  
60 considered an adjunctive infection control measure, and undertaken with knowledge of HEPA filter  
61 functionality and limitations in mind.

62

63

64

65

66 **Introduction**

67 Airborne transmission of the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2),  
68 the causative agent of the Coronavirus disease 2019 (COVID-19), occurs through respiratory droplets  
69 (generally >5 microns) and aerosol droplets (generally <5 microns) that are expectorated from respiratory  
70 tracts of infected individuals.<sup>1</sup> Aerosol generating procedures (AGPs) represent a major concern for  
71 healthcare-associated infection (HAI) of patients and healthcare providers. In comparison to large  
72 droplets, which are rapidly pulled downwards by gravity, aerosols may remain suspended in the air for an  
73 hour or more.<sup>2</sup> Otolaryngology is one medical specialty at particularly high risk of HAI with SARS-CoV-  
74 2 due to commonplace performance of AGPs in the office. Current guidance by the Centers for Disease  
75 Control and Prevention (CDC) is that AGPs be performed in airborne infection isolation rooms (AIIR; i.e.  
76 negative pressure rooms) when possible or otherwise allowing procedure rooms to remain unoccupied  
77 until SARS-CoV-2-laden aerosols may be cleared through other means, e.g. room air exchanges from  
78 indwelling ventilation.<sup>3</sup> The CDC has not provided any recommendations for the use of portable air  
79 purifiers. Nevertheless, air purifiers with high-efficiency particulate air (HEPA) filters have been  
80 discussed as an adjunctive means for decontamination of SARS-CoV-2 aerosols in healthcare  
81 settings. Consideration of portable air purifiers with HEPA filters (HEPA purifiers) during the SARS-  
82 CoV-2 pandemic, however, should be with extensive knowledge about the functionality, efficacy and  
83 limitations of HEPA purifiers.

84

85 **Discussion**

86 **Mechanisms of action**

87 HEPA filters are usually manufactured by pleating microfiber glass or other fibrous media made  
88 with multiple layers of randomly arranged fibers with diameters ranging from 2nm to 500nm.<sup>4</sup> As air  
89 flows through the filter and in between the fibers, airborne particles—such as respiratory and aerosol  
90 droplets—will be trapped by one of three mechanisms: impaction, interception and diffusion, which are

91 illustrated in Figure 1.<sup>5</sup> Adhesion to filter fibers may occur through Van der Waals forces, electrostatic  
92 attraction and capillary action. For particle sizes above 1 $\mu\text{m}$ , impaction and interception are the most  
93 significant mechanisms of filtration whereas diffusion is the dominant mechanism for trapping particles  
94 smaller than 0.1 $\mu\text{m}$ .<sup>4</sup> Particles between 0.1 $\mu\text{m}$  and 1 $\mu\text{m}$  are influenced by all three methods of capture to  
95 a lesser degree than those larger or smaller, which leads to a lower efficiency of filtration.<sup>4</sup>

96

### 97 **Efficacy**

98 To qualify as HEPA grade, filters must remove at least 99.97% of all particles that are 0.15 $\mu\text{m}$  -  
99 0.2 $\mu\text{m}$ , for which HEPA filters are least effective. Thus HEPA filters have at least 99.97% efficiency at  
100 removing all particles, with even higher efficiencies for particles both larger and smaller than 0.15 $\mu\text{m}$   
101 (Figure 2). The interesting U-shaped efficiency curve of all HEPA filters, which has a minimum at  
102 0.15 $\mu\text{m}$ , is due to the relative effectiveness of the three mechanisms of particle capture at various particle  
103 sizes (Figure 2). Filters with efficiencies higher than 99.99% are also termed Ultra Low Penetration Air  
104 (ULPA) filters.

105

### 106 **Clean air delivery rate (CADR)**

107 HEPA purifiers of various sizes and power will remove particles at different rates. The clean air  
108 delivery rate, or CADR, is an important performance parameter created by the Association of Home  
109 Appliance Manufacturers to quantify the cubic feet per minute (CFM) of air completely filtered of a  
110 particle by the air purifier. The CADR is calculated as flow of air through the filtration system  
111 multiplied by the efficiency of filtration of the particular particle. CADR score is specific to particle sizes  
112 and typically reported for three categories of particle sizes designated as pollen (2.5 $\mu\text{m}$  to 80 $\mu\text{m}$ ), dust  
113 (1 $\mu\text{m}$  to 30 $\mu\text{m}$ ) and tobacco smoke (0.1 $\mu\text{m}$  to 1 $\mu\text{m}$ ).<sup>6</sup> The CADR for dust and tobacco smoke may be  
114 most useful for determining filtration rate of aerosols and viruses respectively, which are generally in the  
115 corresponding size range.

116 A previously reported study by the Environmental Protection Agency illustrates practical  
117 considerations for airborne particle decontamination by HEPA purifiers.<sup>2</sup> Assuming complete mixing of  
118 the air during filtration, which was found to be realistic approximation, the amount of time needed to  
119 filter a certain fraction of particles out of a volume of air was derived, using the CADR, as:

$$120 \quad C(t) = C_0 e^{-\left(\frac{\text{CADR}}{V}\right)t}$$

121 where  $C(t)$  is the concentration of the particle as a function of time,  $C_0$  is the initial particle concentration,  
122  $V$  is the volume of the air being filtered and  $t$  is time.<sup>2</sup> Therefore, a HEPA purifier that has a CADR score  
123 of 300 for tobacco smoke (indicating the device removes all tobacco smoke particles from 300 cubic feet  
124 of air every minute), would be expected to clear 99% of all tobacco smoke particles in a 1000 cubic foot  
125 room (e.g., 10x10x10ft) in 15 minutes. Location of HEPA purifier placement within the room and  
126 presence of basic furniture, such as a desk and chair, did not substantially impact efficacy although  
127 pointing the purifier's air intake towards the particle source improved decontamination.<sup>2</sup>

128

### 129 **HEPA filters applied to SARS-CoV-2**

130 The vast majority of aerosols that may be produced by human cough are less than 1 micron in  
131 size<sup>7</sup> and the SARS-CoV-2 virion is reported to be 60nm to 140nm (0.06 $\mu$ m to 0.14 $\mu$ m) in size.<sup>1</sup>  
132 Although the CDC has recommended the use of HEPA filters in powered air purifying respirators  
133 (PAPRs) for effective filtration of SARS-CoV-2,<sup>8</sup> at present the CDC has not provided any  
134 recommendations for the use of portable HEPA purifiers for decontamination of SARS-CoV-2 in clinical  
135 areas or procedure rooms. The U.S. Food and Drug Administration (FDA) recommends that  
136 manufacturers of air purifiers intended for use related to SARS-CoV-2, evaluate effectiveness against a  
137 representative virus.<sup>9</sup> Coincidentally, CDC previously suggested the use of portable HEPA purifiers as an  
138 adjunctive infection control strategy for SARS-CoV-1, the causative agent of the 2003 SARS outbreak.<sup>10</sup>

139

### 140 **Considerations for commercial acquisition of HEPA purifiers**

141 Consumers are cautioned that commercially available air purifiers make claims with labels like  
142 True HEPA, HEPA-like, HEPA-type. However, to be labeled HEPA, a filter is required to be tested and  
143 individually certified according to standards by the U.S. Institute of Environmental Sciences and  
144 Technology (IEST-RP-CC001.6) or the International Organization for Standardization (ISO 29463). Very  
145 few air purifiers meet this requirement. By comparison CADR rating is a more reliable performance  
146 parameter. Medical HEPA air purifiers may additionally claim to have an ultraviolet light or other  
147 decontaminating agent to kill microbes that deposit on the filter itself. In most cases, their microbicidal  
148 effectiveness has not been independently verified. Manufacturer guidelines should be followed for when  
149 to change filters as saturation of filters affects efficiency. Finally, proper personal protective equipment  
150 should be worn to exchange air purifier filters as these filters may contain trapped SARS-CoV-2. Proper  
151 disposal procedures should be followed to avoid contamination.

152

### 153 **Conclusion**

154 At present, there are no formal recommendations by the CDC for use of portable HEPA purifiers  
155 for decontamination of airborne SARS-CoV-2. Knowledge of HEPA filter functionality and prior CDC  
156 guidance for SARS-CoV-1 suggests theoretical efficacy for HEPA filters to remove airborne SARS-CoV-  
157 2, although it is important to emphasize that direct studies for SARS-CoV-2 have not been  
158 performed. Any utilization of portable HEPA purifiers for SARS-CoV-2 should be considered an  
159 adjunctive infection control measure, and be undertaken with knowledge of HEPA filter functionality and  
160 limitations in mind.

161

162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200

**References**

1. Tang D, Comish P, Kang R. The Hallmarks of COVID-19 Disease. PLoS Pathog 2020; 16:e1008536.
2. Kogan V, Harto C, Hesse DJ, Hofacre KC. Final report on evaluation of in-room particulate matter air filtration devices. Office of Research and Development, National Homeland Security Research Center, Decontamination and Consequence Management Division, U.S. Environmental Protection Agency, 2008. Available at: [https://cfpub.epa.gov/si/si\\_public\\_record\\_report.cfm?Lab=NHSRC&subject=Homeland%2520Security%2520Research&dirEntryId=188372](https://cfpub.epa.gov/si/si_public_record_report.cfm?Lab=NHSRC&subject=Homeland%2520Security%2520Research&dirEntryId=188372)
3. Centers for Disease Control and Prevention. "Appendix B. Air: Guidance for Environmental Infection Control in Health-Care Facilities." July 22, 2019. Available at: <https://www.cdc.gov/infectioncontrol/guidelines/environmental/appendix/air.html>. Accessed May 22, 2020.
4. Perry JL, Agui JH, Vijaykumar R. Submicron and nanoparticulate matter removal by HEPA-rated media filters and packed beds of granular materials. . Marshall Space Flight Center: Huntsville, AL: National Aeronautics and Space Administration, 2016.
5. First MW. HEPA filters. J Am Biol Safety Assoc 1998; 3:33-42.
6. Sahu SK, Tiwari M, Bhangare RC, Pandit GG. Particle size distribution of mainstream and exhaled cigarette smoke and predictive deposition in human respiratory tract. Aerosol Air Qual Res 2013; 13:324-332.
7. Lindsley WG, Pearce TA, Hudnall JBet al. Quantity and size distribution of cough-generated aerosol particles produced by influenza patients during and after illness. J Occup Environ Hyg 2012; 9:443-449.
8. Centers for Disease Control and Prevention. "Considerations for Optimizing the Supply of Powered Air-Purifying Respirators (PAPRs): For Healthcare Practitioners (HCP)." April 19, 2020. Available at: <https://www.cdc.gov/coronavirus/2019-ncov/hcp/ppe-strategy/powered-air-purifying-respirators-strategy.html>. Accessed May 22, 2020.
9. U.S. Food and Drug Administration. Enforcement Policy for Sterilizers, Disinfectant Devices, and Air Purifiers During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency: Guidance for Industry and Food and Drug Administration Staff, 2020.
10. Centers for Disease Control and Prevention. "III. Infection Control in Healthcare Facilities: Public Health Guidance for Community-Level Preparedness and Response to Severe Acute Respiratory Syndrome (SARS)." May 3, 2005. Available at: <https://www.cdc.gov/sars/guidance/infection/healthcare.html>. Accessed May 22, 2020.

201

202 **Figure legends**

203 **Figure 1.** Schematic of filtration mechanisms of impaction, interception, and diffusion. © R.

204 Vijayakumar, reproduced with permission.

205 **Figure 2.** HEPA filter efficiency as a function of particle size and filtration mechanism. MPPS = most

206 penetrating particle size. © R. Vijayakumar, reproduced with permission.

207



208

209



*This manuscript has been accepted for publication in Otolaryngology-Head and Neck Surgery.*


# Figure 1



*This manuscript has been accepted for publication in Otolaryngology-Head and Neck Surgery.*

*This manuscript has been accepted for publication in Otolaryngology-Head and Neck Surgery.*

## Figure 2



*This manuscript has been accepted for publication in Otolaryngology-Head and Neck Surgery.*